Seegene Expands Presence in Europe with New Subsidiary
Seegene, a prominent global player in the field of molecular diagnostics, has proudly announced the establishment of its newest subsidiary in France. This marks a significant milestone for the company, as it adds France to its list of overseas sales subsidiaries, now totaling eight, with prior subsidiaries in Italy and Germany.
France stands as Europe's second-largest market for molecular diagnostics, driven largely by the rising demand for testing in areas such as sexually transmitted infections and gastrointestinal illnesses, as well as respiratory viruses. The creation of this new subsidiary comes at a strategic time as Seegene looks to leverage France's growing healthcare industry.
Importance of the French Market
The French molecular diagnostics market is projected to reach around EUR 600 million, representing 15 percent of the total European market. Notably, Germany leads with a market share of 19 percent. There is a particularly strong demand in France for diagnostic tests that address sexually transmitted infections, gastrointestinal infections, and respiratory ailments.
By entering this vibrant market, Seegene aims to enhance the distribution of its existing diagnostic products, while also expanding its portfolio to include tests for cervical cancer and other complex diagnostic categories. This diversification is crucial for meeting the specific healthcare needs within France.
Enhancing Local Customer Engagement
With the establishment of this subsidiary, Seegene intends to bolster its engagement with local customers and healthcare partners. Enhanced technical support and dedicated market development teams will foster collaboration with stakeholders throughout the healthcare system.
Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, emphasizes the importance of innovation and efficiency in the French market, which comprises both public and private sectors. He states that the ability to quickly deliver innovative products is vital for maintaining competitiveness.
Supporting Seegene's Growth Strategy
The new subsidiary will act as a pivotal platform for the rollout of Seegene's developing solutions, such as CURECA™ and STAgora™. CURECA™ is an unmanned, fully automated PCR system poised to revolutionize diagnostics, while STAgora™ will offer real-time diagnostic data analytics and predictive insights, further enhancing the capabilities of healthcare professionals.
Currently, a significant portion of Seegene's revenue is derived from overseas sales, with around 93 percent of total revenue originating from international markets. Within this, Europe accounts for about 63 percent. This reliance underscores the essential role the European market plays in Seegene's overarching growth strategy.
Innovation in Molecular Diagnostics
Seegene's commitment to research and development spans over 25 years, particularly shining during the COVID-19 pandemic when the company facilitated the provision of over 340 million tests to more than 100 countries. Their innovative syndromic real-time PCR technology stands out for its capability to test for multiple pathogens causing similar symptoms simultaneously, delivering crucial results in one test tube.
As France joins the ranks of Seegene's international subsidiaries, the company remains committed to fostering local expertise and enhancing service quality across its markets. This initiative is at the heart of Seegene's strategy to meet the evolving demands of the healthcare landscape.
Frequently Asked Questions
1. What is Seegene's new subsidiary in France focused on?
The new subsidiary aims to enhance local customer engagement, support market development, and promote Seegene's innovative diagnostic solutions in France.
2. How significant is the French molecular diagnostics market?
France is the second-largest market in Europe, estimated to reach EUR 600 million and accounting for about 15% of the total European market.
3. What solutions are being introduced in the French market?
Seegene plans to introduce diagnostic tests for sexually transmitted infections, gastrointestinal tract infections, and expand its offerings to include cervical cancer tests.
4. How does Seegene maintain its competitive edge in France?
By rapidly delivering innovative products and enhancing technical support tailored to the needs of local laboratories and healthcare providers.
5. What is the company’s global sales strategy?
Seegene's strategy focuses on expanding its footprint through overseas sales, with significant contributions from the European market, driving overall revenue growth.
